^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    mRNA-4359

    i
    Other names: mRNA-4359, mRNA4359, mRNA 4359
    Associations

    News

    Trials
    Company:
    Moderna
    Drug class:
    PD-L1 inhibitor, Immunostimulant, IDO inhibitor
    Related drugs:
    Associations

    News

    Trials
    2ms
    Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=361, Recruiting, ModernaTX, Inc. | N=194 --> 361 | Trial completion date: Dec 2027 --> Feb 2032 | Trial primary completion date: Dec 2027 --> Feb 2032
    Enrollment change • Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • mRNA-4359
    3years
    Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=194, Recruiting, ModernaTX, Inc.
    New P1/2 trial • Combination therapy • Checkpoint inhibition
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3)
    |
    Keytruda (pembrolizumab) • mRNA-4359